What Avance Clinical does

Avance Clinical is an Australia-headquartered, full-service Contract Research Organization (CRO) that provides clinical trial management services to international biotechnology sponsors across all development phases. Its core offering combines preclinical and regulatory consultancy (ClinicReady), early-phase services leveraging Australia's Clinical Trial Notification scheme (no IND requirement, 5-6 week study start-up timelines), late-phase multi-regional trials, and the proprietary GlobalReady end-to-end drug development model that retains the same CRO team and data quality from Phase I in Australia through late-phase expansion into North America, Asia-Pacific, and Europe. The company supplements this platform with four specialized Centers of Excellence in Oncology, CNS, Renal & Cardiometabolic, and Early Phase, each providing indication-level scientific leadership and dedicated trial design capabilities.

The company operates a 2,000+ site GlobalReady Site Partnership Network across North America and maintains offices in Australia, New Zealand, the United States, the United Kingdom, South Korea, Taiwan, Singapore, Malaysia, mainland China (Shanghai, Beijing), and India. Its technology stack integrates Medidata-trained platform specialists, electronic health records integration, digital patient engagement, and what the company describes as AI-enabled clinical trial management systems. Since 2022, Avance Clinical has been privately held and backed by Riverside following a significant investment that valued the company above $200 million.

The business model is project-based full-service CRO revenue: multi-year contracts with biotech sponsors priced per study scope, phase, and therapeutic area, with no public pricing. Australia's 43.5% R&D tax rebate on eligible clinical spend effectively reduces net cost for sponsors, a key component of the value proposition. Go-to-market is primarily enterprise field sales supplemented by inside sales (website "Request a Proposal" and "Book a Meeting" funnels), with concentrated event presence at BIO International, ASCO, AACR, and BIO-Europe driving top-of-funnel lead generation. The company employs 330+ experienced staff and reports 500+ studies completed, 18,000+ participants recruited, and 70% repeat customer rates over the past five years.

Name

Avance Clinical

Legal name

Avance Clinical Pty Ltd.

Website

https://www.avancecro.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

251–500 employees

Short description

Avance Clinical is an Australia-headquartered global CRO providing full-service clinical trial management for international biotech sponsors across preclinical, early-phase, and late-phase development, leveraging Australia's regulatory advantages and a proprietary GlobalReady model spanning Australia, North America, Asia-Pacific, and Europe.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB), Medical Writing & Regulatory Submission Support CROs (HLAGAAAG), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH)

Keywords

• Clinical research services
• Contract research organization
• Early phase trials
• Biotech clinical development
• Oncology clinical trials

Headquarters

HQ city

Thebarton

HQ country

Australia

HQ region

Oceania

Offices9 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Contract Research Organization Services: Avance Clinical generates revenue through full-service contract research organization services for biotech companies, providing clinical trial management from preclinical through Phase I, Phase II, and late-phase studies. Revenue is project-based, typically structured as fixed contracts for defined scope of work.

Pricing tiers

Go-to-market motion3 records

Distribution channels2 records

Marketing channels6 records

Core offering

Avance Clinical is a full-service Contract Research Organization (CRO) providing clinical trial management services for biotech companies from preclinical through late-phase development. Its offerings span the ClinicReady preclinical consultancy, Phase I and Early Phase trials, Phase II+ and Late Phase multi-regional studies, and the proprietary GlobalReady end-to-end drug development process. The company also operates specialized Centers of Excellence in CNS, Oncology, Renal & Cardiometabolic, and Early Phase, serving biotech sponsors across Australia, North America, Asia, New Zealand, and Europe.

Product overview

Avance Clinical is a full-service Contract Research Organization (CRO) offering an integrated platform of clinical trial services for biotech companies. The core offering includes ClinicReady (preclinical and regulatory affairs consultancy), Phase I/Early Phase services, Phase II+/Late Phase services, and the GlobalReady proprietary drug development model spanning all phases across multiple regions. Specialized Centers of Excellence in CNS, Oncology, Renal & Cardiometabolic, and Early Phase provide indication-specific expertise. The company operates across Australia, North America, Asia, New Zealand, and Europe, leveraging Australia's regulatory advantages including rapid ethics approval, no IND requirement, and up to 43.5% R&D tax rebate.

Differentiator

Problem solved

Functional benefit

Brands

• GlobalReady: A proprietary process encapsulating the entire drug development journey from robust Early Phase clinical foundations to seamless multi-regional Late phase expansions, retaining the same high quality CRO to reduce time and cost and deliver highest quality data for regulatory approvals.
• ClinicReady
• Early Phase Center of Excellence
• Oncology Center of Excellence
• CNS Center of Excellence
• Renal & Cardiometabolic Center of Excellence

Products and services

• ClinicReady Preclinical and regulatory affairs consultancy service that helps biotech sponsors demonstrate safety and preliminary clinical Proof of Concept, laying clinical foundations for seamless transition into Phase I. Target users: biotech sponsors preparing for first-in-human studies.
• Phase I / Early Phase Services Comprehensive Phase I clinical trial services offering fast, agile, and adaptive clinical research solutions for biotechs in early phases of drug development. Target users: biotech sponsors conducting first-in-human and early-phase studies.
• Phase II+ / Late Phase Services Multi-regional clinical trial services for Phase II and later, across oncology, CNS, rare diseases, and infectious diseases, leveraging AI and gold standard data and trial management systems. Target users: biotech sponsors running late-stage multi-regional trials.
• GlobalReady Proprietary end-to-end drug development service retaining the same CRO team from Phase I in Australia through multi-regional late-phase expansion in the US, Asia-Pacific, and Europe, delivering globally accepted data for regulatory approvals. Target users: biotech sponsors seeking a single CRO partner across all development phases and geographies.
• CNS Center of Excellence Specialized clinical trial services for central nervous system disorders, addressing trial challenges for biotech sponsors developing neurological therapies, supported by experienced leadership and strategic partnerships. Target users: biotech sponsors developing CNS therapeutics.
• Oncology Center of Excellence Specialized oncology clinical trial services combining indication-level scientific leadership, advanced early-phase trial design, and oncology-focused site networks to support confident progression from first-in-human through Phase II. Target users: biotech sponsors developing oncology therapeutics.
• Renal & Cardiometabolic Center of Excellence Specialized clinical trial services focused on improving patient recruitment, retention, and speeding up clinical development in renal and cardiometabolic therapeutic areas. Target users: biotech sponsors developing renal and cardiometabolic therapies.
• Early Phase Center of Excellence Dedicated center accelerating high-quality early-phase trials for emerging biotech sponsors, operating through a globally integrated model across Australia, New Zealand, the United States, the United Kingdom, South Korea, Taiwan, and India. Target users: emerging biotech sponsors requiring rapid early-phase execution.

Quantifiable outcome

• 5-6 weeks to Site Initiation Visit and Study Start in Australia
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Partnerships

Six partnerships are on record, tiered core, major and supporting.

• Calidi BiotherapeuticscoreStrategic or Co-development Partner · 24 March 2026Partnership for CLD-401 oncolytic virus clinical trials in Australia, facilitating regulatory approval and initiating clinical trials for solid tumor indications. Calidi plans to file IND with FDA in 2026.
• LumaBridgecoreStrategic or Co-development Partner · 7 January 2026Acquisition of U.S.-based specialized oncology CRO with deep expertise in oncology trials, strengthening Avance Clinical's global oncology offering.
• Simbec-OrionmajorStrategic or Co-development Partner · 26 February 2025Strategic partnership agreement signed February 26, 2025, forming collaborative framework between two full-service CROs to deliver globally integrated clinical trial solutions. Partnership enables Simbec-Orion expansion into Australia and Asia-Pacific while extending Avance Clinical capabilities in Europe and UK, combining expertise across 34 countries.
• Mid-Ship BiomedicalsupportingStrategic or Co-development PartnerMOU signed to strengthen global clinical research collaboration between the two organizations.
• Four Premier Taiwanese Trial SitessupportingStrategic or Co-development PartnerMOUs signed with key clinical trial sites in Taiwan providing sponsors priority access to eligible patients and accelerating clinical trial agreement finalization.
• Matica BiosupportingTechnology or IntegrationGMP manufacturer partnership for CLD-401 manufacturing supporting Calidi Biotherapeutics clinical program.

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• PPD (Thermo Fisher Scientific): Global CRO acquired by Thermo Fisher Scientific offering full-service clinical development across all phases. PPD is a broad incumbent competitor to Avance Clinical in late-phase and multi-regional biotech clinical trials.
• Parexel: Large global CRO offering comprehensive clinical development and biopharmaceutical services. Parexel directly competes for multi-regional biotech clinical trial mandates that Avance Clinical also targets under its GlobalReady model.
• Medpace: Mid-to-large CRO specializing in clinical development for small and mid-sized biopharma. Medpace competes with Avance Clinical in the biotech-focused CRO segment but with a US-centric operating model and broader scale.
• ICON plc: One of the world's largest CROs providing full-service clinical development across all phases and therapeutic areas. ICON competes with Avance Clinical for biotech sponsor business but operates at significantly greater scale with broader service offerings.
• Labcorp Drug Development: Global CRO formed from the Covance acquisition, providing full-service clinical development and central laboratory services. Labcorp competes with Avance Clinical in early and late-phase trials but with significantly broader infrastructure and central lab capabilities.
• IQVIA: The largest global CRO with end-to-end clinical, technology, and data capabilities. IQVIA is a broad incumbent competitor that offers similar multi-regional biotech CRO services as part of a much larger portfolio including RWD and commercial services.
• Charles River Laboratories: Large CRO and preclinical services provider offering research models, discovery, and clinical development support. Charles River competes with Avance Clinical's ClinicReady preclinical offering and selected clinical services, though from a much larger discovery-focused platform.

Direct peers

• Worldwide Clinical Trials: Mid-sized global CRO with deep CNS, oncology, and rare disease expertise. Worldwide is a comparable mid-tier competitor targeting similar biotech sponsor profiles with overlapping therapeutic area specializations.
• Simbec-Orion: Mid-sized full-service clinical CRO with strong early-phase and specialty therapeutic expertise. Simbec-Orion is both a strategic partner (Feb 2025 alliance) and a direct peer in the biotech-focused CRO segment, with overlapping therapeutic and geographic coverage.
• Novotech: Asia-Pacific-headquartered full-service CRO focused on biotech clinical trials across the region, with strong early-phase capabilities. Novotech is the most direct geographic and segment competitor to Avance Clinical in the biotech-focused, multi-regional CRO market.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/Avance_Clinical_CRO-171912947893280
• LinkedInlinkedin.com/company/avance-clinical

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avance Clinical